Skip to main content
Annals of Clinical BiochemistryVolume 28, Issue 6, 1991, Pages 595-598

Plasma C1 inhibitor in malignant diseases: Functional activity versus concentration(Article)

  Save all to author list
  • Department of Biochemistry, Pharmaceutical Faculty, Dr Subotica 8, PO Box 146, 11000 Belgrade

Abstract

Plasma C1 inhibitor (C1-INH) was determined in 64 patients with different malignant diseases and in 58 healthy persons. Cl-INH antigen concentration was measured by radial immunodiffusion (RID), whereas its functional activity was assayed with chromogenic substrate. Within-run and day-to-day precision of both methods were good, with CVs ranging from 3.6 to 5.4%. Plasma C1-INH antigen concentrations were significantly higher in the patients than in healthy controls (P=4.0 x 10-3), as were their C1-INH functional activities (P=3.5 x 10-3). C1-INH activities obtained in the patient plasma samples were in correlation with their antigen concentrations (r = 0.914), showing that C1-INH synthesized in malignant disease was functional. However, the specific activity of the C1-INH (functional activity/antigen concentration ratio) was significantly lower in the patient group as compared with the controls (P=2.1 x 10-6), indicating partial inactivation of plasma C1-INH in malignant diseases. The C1-INH specific activity in patients was inversely proportional to its antigen concentration.

Author keywords

Chromogenic substrateComplementRadial immunodiffusion

Indexed keywords

EMTREE drug terms:antigenchromogenic substratecomplement component C1s inhibitor
EMTREE medical terms:articlecancer cellconcentrationcontrolled studyfemalefunctional assessmenthumanhuman tissueimmunodiffusionleukemialymphomamajor clinical studymalemalignant neoplastic diseaseplasmaplasmacytomapriority journalsolid tumor

Chemicals and CAS Registry Numbers:

complement component C1s inhibitor, 80295-37-0, 80295-38-1

  • ISSN: 00045632
  • CODEN: ACBOB
  • Source Type: Journal
  • Original language: English
  • DOI: 10.1177/000456329102800609
  • PubMed ID: 1776810
  • Document Type: Article

  Jelic-Ivanovic, Z.; Department of Biochemistry, Pharmaceutical Faculty, Dr Subotica 8, PO Box 146,
© Copyright 2017 Elsevier B.V., All rights reserved.

Cited by 6 documents

Lee, C.-S. , Taib, N.A.M. , Ashrafzadeh, A.
Unmasking heavily O-glycosylated serum proteins using perchloric acid: Identification of serum proteoglycan 4 and protease C1 inhibitor as molecular indicators for screening of breast cancer
(2016) PLoS ONE
Varga, L. , Dobó, J.
C1 inhibitor: Quantification and purification
(2014) Methods in Molecular Biology
O-Charoenrat, P. , Rusch, V. , Talbot, S.G.
Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung
(2004) Clinical Cancer Research
View details of all 6 citations

SciVal Topic Prominence

Topic:
Prominence percentile: